Sleep Disorders

Cognitive behavioral therapy for insomnia effectively treats chronic insomnia, promoting long-term sleep improvement through targeted behavioral strategies.

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Explore effective strategies for managing narcolepsy, including personalized treatment plans, medication options, and lifestyle interventions for improved patient outcomes.

Discover the complexities of sleep-related eating disorder, its symptoms, triggers, and effective treatments for better sleep health.

Apnimed reveals promising results for AD109, a groundbreaking oral treatment for obstructive sleep apnea.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

What is a sleep disorder? Explore the complexities of their definitions and the impact of circadian rhythms on health and well-being.

Explore the intricate relationship between sleep disorders and psychiatric conditions, diagnostic challenges, and effective management strategies, in this Special Report article.

Explore the complex relationship between insomnia and mental health, and learn more about effective treatments like CBT-I for better sleep and well-being.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Discover the unique approaches to treating sleep disorders in children vs adults, highlighting effective behavioral strategies.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.

Do you want to be featured in a future Special Report? Check out our April theme!

In the phase 3 ENCORE trial, AXS-12 reduced the frequency of cataplexy attacks as compared with placebo at week 3 of the double-blind period.

Brain injury was recently recognized as a chronic health condition.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

Will this help my sleep and mood? Researchers investigated the effects of noninvasive neurostimulation on sleep quality and depressive symptoms in patients with major depressive disorder in a meta-analysis of randomized controlled trials.

Sleep and suicide? Researchers investigated improvement in insomnia as a pathway underlying the antisuicidal properties of clozapine.

The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.

Here are highlights from the week in Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

An expert discusses how the risks of benzodiazepine prescribing have been exaggerated in the minds of government officials, critics, and the public at large.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.